India offering ‘far deeper’ proposals in RCEP: Rita Teaotia

Source: PTI Published: The Economic Times | March 27, 2017

NEW DELHI: Pitching for liberalisation of trade in services, India today said it is offering “far deeper” proposals in the proposed mega deal RCEP than most of the other member nations of the grouping.

The Regional Comprehensive Economic Partnership (RCEP) is a mega trade agreement being negotiated among 16 countries including ASEAN, India, China, Japan, South Korea, Australia and New Zealand. Continue reading

Posted in IPR, Regional Comprehensive Economic Partnership, Uncategorized | Leave a comment

Jane Kelsey: Governments in denial of a world changing around them

Source: NZHerald | March 29, 2017

The visit of China’s Premier Le Keqiang to New Zealand should be the catalyst for a mature and nuanced discussion of our future relationship with the world’s rising hegemon, not simply, whether we can renegotiate the China New Zealand free trade agreement to gain more dairy market access, and will we give China more investment rights and protections in return.

An important backdrop for this reflection is the crisis meeting Chile convened last week to plan the rescue of the Trans-Pacific Partnership (TPP) agreement and the broader, troubled free-trade and investment model. Continue reading

Posted in Investor state dispute, Regional Comprehensive Economic Partnership, TPP, Uncategorized | Leave a comment

Switzerland wants stricter intellectual property rules in India that could harm generic drug makers

By Jyotsna Singh, Scroll | March 23, 2017

Developed countries continue to put pressure on India to move to stricter intellectual property regimes that would favour multinational pharmaceutical countries over generic drug manufacturers. A new leaked document shows that the Swiss government is pushing for more patent protections and data exclusivity in negotiations for the Trade and Economic Partnership Agreement or TEPA between India and the European Free Trade Association being held in New Delhi. Continue reading

Posted in Data Exclusivity, EFTA-India FTA, Evergreening, Patent, Uncategorized | Leave a comment

Panel Rejects Eli Lilly Claim Over Canadian Patent Law, Orders Company to Pay Millions in Costs

In the early 1990s, Eli Lilly applied for patent protection in Canada for two chemical compounds, olanzapine and atomoxetine. The company had already obtained patents over the compounds, but asserted that it had evidence to support new uses for the compounds that merited further protection. The Canadian patent office granted the patents based on the content in the applications, but they remained subject to challenge. Continue reading

Posted in Investor state dispute, NAFTA, Special 301 report, Uncategorized, USTR, USTR 301 report | Leave a comment

Study & video released about the impact of the Mercosur/EU FTA on access to medicines in Brazil

This week (March 20-24, 2017) negotiators of the European Union and Mercosur meet once again to move forward with the negotiation of a Free Trade Agreement (FTA). This FTA could have a great impact not only on trade, but in people’s rights, including access to medicines. Continue reading
Posted in EU-Mercosur FTA under FTA, TRIPS plus, Uncategorized | Leave a comment

European FTA pushes for tougher IPR rules under ongoing trade talks with India

Switzerland proposed that India agree to broader patentable principles, as per a leaked note on the proposed Intellectual Property Rights chapter of the talks

Posted in Uncategorized, Data Exclusivity, Evergreening, EFTA-India FTA, Patent, IPR | Leave a comment

India–EFTA trade talks may make medicines more expensive

MSF and civil society urge Swiss negotiators not to undermine the ‘pharmacy of the developing world’  

Geneva/New Delhi, 22March 2017 – Asintellectual property (IP) negotiators from India andthe four countries from EFTA (European Free Trade Association) meeting New Delhi this week to resume talks,Médecins Sans Frontières (MSF), International Treatment Preparedness Coalition,and Public Eye warn that Swiss negotiators are demanding the inclusion of harmful intellectual property measures that could adversely impact access to medicines. EFTA is a trade bloc of four European countries outside of the European Union, made up of Switzerland, Iceland, Norway and Liechtenstein. Continue reading

Posted in Data Exclusivity, EFTA-India FTA, Evergreening, Patent, Sec 3 (d), Uncategorized | Leave a comment